1469439-69-7

Basic information

• Product Name: 6-fluoro-2-[4-(morpholinomethyl)phenyl]-N-(2-pyrrolidin-1-ylethyl)quinoline-4-carboxamide
• CAS NO: 1469439-69-7
• Molecular Weight: 462.567
• Mol File: 1469439-69-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 649.5±55.0 °C(Predicted)
• Density: 1.229±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 6-fluoro-2-[4-(morpholinomethyl)phenyl]-N-(2-pyrrolidin-1-ylethyl)quinoline-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 6-fluoro-2-[4-(morpholinomethyl)phenyl]-N-(2-pyrrolidin-1-ylethyl)quinoline-4-carboxamide(1469439-69-7)
• EPA Substance Registry System: 6-fluoro-2-[4-(morpholinomethyl)phenyl]-N-(2-pyrrolidin-1-ylethyl)quinoline-4-carboxamide(1469439-69-7)

Safety Data

• Hazardous Substances Data: 1469439-69-7(Hazardous Substances Data)

Usage

General Description

The chemical compound "6-fluoro-2-[4-(morpholinomethyl)phenyl]-N-(2-pyrrolidin-1-ylethyl)quinoline-4-carboxamide" is a complex molecule with multiple functional groups. It contains a quinoline core with a fluoro substituent at the 6-position, as well as a N-(2-pyrrolidin-1-ylethyl) group attached to the quinoline. Additionally, it features a 4-carboxamide and a 4-(morpholinomethyl)phenyl group. 6-fluoro-2-[4-(morpholinomethyl)phenyl]-N-(2-pyrrolidin-1-ylethyl)quinoline-4-carboxamide may have potential pharmacological or biological activities due to the presence of these specific functional groups, and further research and investigation may be necessary to determine its specific properties and potential applications.

Upstream product

• 7154-73-6 1-(2-aminoethyl)pyrrolidine 
• 607-40-9 6-fluoro-2-hydroxy-quinoline-4-carboxylic acid 
• 265107-94-6 1-(4-(morpholinomethyl)phenyl)ethan-1-one 
• 17201-43-3 4-cyanobenzyl bromide 
• 37812-51-4 4-(morpholin-4-ylmethyl)benzonitrile 
• 1335234-36-0 [4-(morpholinomethyl)phenyl]boronic acid hydrochloride 
• 443-69-6 5-fluoro-1H-indole-2,3-dione 

Relevant articles and documents

A novel multiple-stage antimalarial agent that inhibits protein synthesis

There is an urgent need for new drugs to treat malaria, with broad therapeutic potential and novel modes of action, to widen the scope of treatment and to overcome emerging drug resistance. Here we describe the discovery of DDD107498, a compound with a po

Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy

The antiplasmodial activity, DMPK properties, and efficacy of a series of quinoline-4-carboxamides are described. This series was identified from a phenotypic screen against the blood stage of Plasmodium falciparum (3D7) and displayed moderate potency but with suboptimal physicochemical properties and poor microsomal stability. The screening hit (1, EC50 = 120 nM) was optimized to lead molecules with low nanomolar in vitro potency. Improvement of the pharmacokinetic profile led to several compounds showing excellent oral efficacy in the P. berghei malaria mouse model with ED90 values below 1 mg/kg when dosed orally for 4 days. The favorable potency, selectivity, DMPK properties, and efficacy coupled with a novel mechanism of action, inhibition of translation elongation factor 2 (PfEF2), led to progression of 2 (DDD107498) to preclinical development.

ANTI-MALARIAL AGENTS

The present invention relates to a novel class of quinolone-4-carboxamide Pf3D7 inhibitors of general formula (I) (Formula (I)) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and in the treatment of malaria in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.